Unknown

Dataset Information

0

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.


ABSTRACT:

Objective

Tanezumab is a new therapeutic intervention for patients with osteoarthritis (OA) of the knee. We performed the present meta-analysis to appraise the efficacy and safety of tanezumab for patients with knee OA.

Methods

We systematically searched randomized controlled trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The primary outcomes were mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, the WOMAC physical function and patient's global assessment (PGA). Outcomes were reported as the standard mean difference (SMD) or relative risk (RR) with 95% confidence interval (CI). We assessed the pooled data using a random-effects model.

Results

Of the identified studies, four were eligible and were included in this meta-analysis (N = 1839 participants). Compared with the placebo groups, tanezumab yielded a significant reduction in mean change in the WOMAC pain (SMD = 0.51, 95% CI 0.34 to 0.69, P<0.00001), the WOMAC physical function (SMD = 0.56, 95% CI 0.38 to 0.74, P<0.00001) and PGA (SMD = 0.34, 95% CI 0.22 to 0.47, P<0.00001). There was no significant difference in serious adverse events (RR = 1.06, 95% CI 0.59 to 1.92, P = 0.84) between the tanezumab and placebo groups. Tanezumab significantly increased discontinuations due to adverse events (RR = 2.89, 95% CI 1.59 to 5.26, P = 0.0005), abnormal peripheral sensations (RR = 3.14, 95% CI 2.12 to 4.66, P<0.00001), and peripheral neuropathy (RR = 6.05, 95% CI 2.32 to 15.81, P = 0.0002).

Conclusion

Tanezumab can alleviate pain and improve function for patients with OA of the knee. However, considering the limited number of studies, this conclusion should be interpreted cautiously and more clinical randomized controlled trials are needed to verify the efficacy and safety of tanezumab for OA of the knee.

SUBMITTER: Kan SL 

PROVIDER: S-EPMC4905652 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.

Kan Shun-Li SL   Li Yan Y   Ning Guang-Zhi GZ   Yuan Zhi-Fang ZF   Chen Ling-Xiao LX   Bi Ming-Chao MC   Sun Jing-Cheng JC   Feng Shi-Qing SQ  

PloS one 20160613 6


<h4>Objective</h4>Tanezumab is a new therapeutic intervention for patients with osteoarthritis (OA) of the knee. We performed the present meta-analysis to appraise the efficacy and safety of tanezumab for patients with knee OA.<h4>Methods</h4>We systematically searched randomized controlled trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The primary outcomes were mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC  ...[more]

Similar Datasets

| S-EPMC5764290 | biostudies-literature
| S-EPMC6896791 | biostudies-literature
| S-EPMC8232525 | biostudies-literature
| S-EPMC6430070 | biostudies-literature
| S-EPMC8579990 | biostudies-literature
| S-EPMC6613301 | biostudies-literature
| S-EPMC9241212 | biostudies-literature
| S-EPMC8777347 | biostudies-literature
| S-EPMC6492327 | biostudies-other
| S-EPMC4998779 | biostudies-literature